As a primary point of contact for patients, the role of the nurse is pivotal to the continuum of care. While this can be true for any patient, it is especially true for hematology patients undergoing immunotherapy.
In supporting the patient or caregiver, the nurse will assist countless times throughout the course of the patient journey. This assistance can take many forms, including discussions on disease-management options, consent, treatment, identification and monitoring of adverse events, and coordination of the multidisciplinary team. Because treatments are often administered in regional specialized centers, isolation and anxiety can add to an already uncertain future caused by a poor prognosis: The nurse becomes the patient's compass and ensures a comprehensive approach to a complex situation.
By giving more nurses greater access to the specialized immunotherapy knowledge and skills needed to actively role manage their patients, and by creating an online environment that nurtures a transparent exchange of ideas, information, and intelligence, we are helping more nurses to make a difference. We believe medical education should be for everyone.
The role of the coordinator nurse in the CAR-T treatment
In this video, Marlene Vercasson, from the Lyon Hospital, shares her experience in the local CAR-T program and Juliet international clinical trial. She reviews the many tasks appointed to the coordinator nurse, in adapting care to the individual patient and making contacts with the Apheresis department, Tissue and Cells Bank, Hematology...
Do mAbs and paraprotein affect COVID-19 Serological Testing in Patients with Mul...
SARS-CoV-2 (COVID-19) serology tests do not appear to interfere or cause cross-reactivity with therapeutic monoclonal antibody (t-mAb) treatments for hematologic malignancies (HM) such as multiple myeloma (MM), according to a study published in Diagnostics.
CAR T-Cell Therapy Improves Blood Cancer, But Toxicities Are Still Concerning
In an interview with OncLive, during the 2020 Institutional Perspectives in Cancer webinar on Leukemia and Lymphoma, Olalekan O. Oluwole, MBBS, MD, who is an assistant professor of medicine, hematology, and oncology at Vanderbilt-Ingram Cancer Center, highlighted the evolution of CAR T-cell therapy in leukemia and lymphoma, targets under investigation, and next steps for exploration.
Promising Response Rates Build Excitement for CAR T-Cell Therapy in Myeloma
Anwer, an oncologist, physician-scientist, and stem cell transplant staff physician at the Taussig Cancer Center of Cleveland Clinic, discussed the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need.
CAR T-Cell Therapy: High Response Rates, High Toxicity Rates
Andrew D. Zelenetz, MD, PhD, medical oncologist and medical director of quality informatics at Memorial Sloan Kettering Cancer Center recently discussed CAR T-cell therapy for this patient population at the NCCN 2020 Virtual Congress on Hematologic Malignancies.
Cancer immunotherapy update
Because cancer treatment (surgery, radiation, and chemotherapy) frequently fails, researchers began asking why patients’ immune systems don’t respond to cancer cells like they do to bacteria and viruses.
A Beginners Guide to Immunotherapy
In this half-day course, Dr Vickers describes the logic behind many immunotherapies for cancer such as checkpoint inhibitors and more.
Immunotherapy Side Effects: What Nurses Should Look Out For
As immunotherapy evolves it is crucial that nurses know the dangerous AEs to look out for.
Apheresis in adults and pediatrics
Access this patient care session on Apheresis in adults and pediatrics, by Daphna Hutt, from the 2nd European CAR T Meeting (2020).
EHA Guidance Document: The Process of CAR T-Cell Therapy in Europe
This document has been created to provide practical guidance for centers and national authorities in Europe that are interested in introducing chimeric antigen receptor (CAR)-T cell therapy.